ClinicalTrials.gg
CompletedNCT06027437Updated Nov 29, 2023

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

A Phase 1 interventional study of Danicamtiv in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the relative biological availability and the effect of food on the drug levels of Danicamtiv in health adults.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BMS-986434
  • MYK-491
  • Healthy
  • Biological Availability
  • Food Effect
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18.0 kg/m2 to 30.0 kg/m2 inclusive
  • Participants with resting heart rate ≥ 55 bpm
  • Seasonal allergies that do not require medication at the time of the study are acceptable

Exclusion criteria

Exclusion Criteria:

  • Any acute or chronic medical illness
  • Head injury, intracranial tumor, or aneurysm within 2 years prior to screening
  • History of chronic gastrointestinal disorders or gastrointestinal (GI) surgery (including cholecystectomy) that could impact on drug and food absorption and/or drug excretion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Treatment A

    Drug: Danicamtiv

  • Experimental
    Treatment B

    Drug: Danicamtiv

  • Experimental
    Treatment C

    Drug: Danicamtiv

Interventions

  • Specified dose on specified days.

    Also known as: BMS-986434, MYK-491

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to day 16

  2. Area under the plasma concentration time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to day 16

  3. Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))

    Time frame: Up to day 16

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to day 16

  2. Terminal elimination half-life (T-HALF)

    Time frame: Up to day 16

  3. Apparent total body clearance (CLT/F)

    Time frame: Up to day 16

  4. Apparent volume of distribution (Vz/F)

    Time frame: Up to day 16

  5. Number of participants with Adverse Events (AEs)

    Time frame: Up to day 43

  6. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to day 43

  7. Number of participants with vital sign abnormalities

    Time frame: Up to day 16

  8. Number of participants with Electrocardiogram (ECG) abnormalities

    Time frame: Up to day 16

  9. Number of participants with Physical Examination (PE) abnormalities

    Time frame: Up to day 16

  10. Number of participants with clinical laboratory abnormalities

    Time frame: Up to day 16

07

Study locations

1 site
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Nov 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 7, 2023
StartActual
Sep 5, 2023
Primary completionActual
Nov 10, 2023
CompletionActual
Nov 10, 2023
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06027437
Responsible party
Sponsor
First posted
Sep 7, 2023
Start date
Sep 5, 2023
Primary completion
Nov 10, 2023
Completion
Nov 10, 2023
Last update
Nov 29, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danicamtiv

Start the discussion